IDH1 and glioblastoma: To overcome the limitations of prior studies, we performed an in-depth analysis of patients with newly diagnosed and recurrent IDH wild-type glioblastoma treated with LITT to better understand the optimal timing and integration of this therapy into the treatment of molecularly defined glioblastoma.